Fosamprenavir or Atazanavir Once Daily Boosted with Ritonavir 100 Mg, Plus Tenofovir/emtricitabine, for the Initial Treatment of HIV Infection: 48-week Results of ALERT

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2008 Apr 1

PMID 18373851

Citations 24

Authors

Kimberly Y Smith

Winkler G Weinberg

Edwin DeJesus

Margaret A Fischl

Qiming Liao

Lisa L Ross

Gary E Pakes

Keith A Pappa

C Tracey Lancaster

Affiliations

Soon will be listed here.

Abstract

Background: Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral treatment. To address this data gap, we conducted an open-label, multicenter 48-week study (ALERT) in 106 antiretroviral-naïve, HIV-infected patients (median HIV-1 RNA 4.9 log10 copies/mL; CD4+ count 191 cells/mm3) randomly assigned to the FPV/r100 or ATV/r100 regimens.

Results: At baseline, the FPV/r100 or ATV/r100 arms were well-matched for HIV-1 RNA (median, 4.9 log10 copies/mL [both]), CD4+ count (mean, 176 vs 205 cells/mm3). At week 48, intent-to-treat: missing/discontinuation = failure analysis showed similar responses to FPV/r100 and ATV/r100 (HIV-1 RNA < 50 copies/mL: 75% (40/53) vs 83% (44/53), p = 0.34 [Cochran-Mantel-Haenszel test]); mean CD4+ count change-from-baseline: +170 vs +183 cells/mm3, p = 0.398 [Wilcoxon rank sum test]). Fasting total/LDL/HDL-cholesterol changes-from-baseline were also similar, although week 48 median fasting triglycerides were higher with FPV/r100 (150 vs 131 mg/dL). FPV/r100-treated patients experienced fewer treatment-related grade 2-4 adverse events (15% vs 57%), with differences driven by ATV-related hyperbilirubinemia. Three patients discontinued TDF/FTC because their GFR decreased to <50 mL/min.

Conclusion: The all-QD regimens of FPV/r100 and ATV/r100, plus TDF/FTC, provided similar virologic, CD4+ response, and fasting total/LDL/HDL-cholesterol changes through 48 weeks. Fewer FPV/r100-treated patients experienced treatment-related grade 2-4 adverse events.

Citing Articles

Identification of potential antivirals against SARS-CoV-2 using virtual screening method.

Rahman M, Banik A, Chowdhury I, Sajib E, Sarkar S Inform Med Unlocked. 2021; 23:100531.

PMID: 33594342 PMC: 7874919. DOI: 10.1016/j.imu.2021.100531.

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.

Snedecor S, Radford M, Kratochvil D, Grove R, Punekar Y BMC Infect Dis. 2019; 19(1):484.

PMID: 31146698 PMC: 6543679. DOI: 10.1186/s12879-019-3975-6.

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.

Ross L, Shortino D, Shaefer M AIDS Res Hum Retroviruses. 2018; 34(8):672-679.

PMID: 29732898 PMC: 6080107. DOI: 10.1089/AID.2017.0295.

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.

Crutchley R, Guduru R, Cheng A HIV AIDS (Auckl). 2016; 8:47-65.

PMID: 27022304 PMC: 4790521. DOI: 10.2147/HIV.S99063.

Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.

Cure S, Bianic F, Espinas C, Hardy H, Rosenblatt L, Juday T PLoS One. 2015; 10(5):e0124666.

PMID: 25938588 PMC: 4418798. DOI: 10.1371/journal.pone.0124666.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Gupta S . Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008; 22(2):99-103. DOI: 10.1089/apc.2007.0052. View

Fux C, Simcock M, Wolbers M, Bucher H, Hirschel B, Opravil M . Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2008; 12(8):1165-73. View

Boffito M, Pozniak A, Kearney B, Higgs C, Mathias A, Zhong L . Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob Agents Chemother. 2005; 49(10):4386-9. PMC: 1251521. DOI: 10.1128/AAC.49.10.4386-4389.2005. View

Squires K, Lazzarin A, Gatell J, Powderly W, Pokrovskiy V, Delfraissy J . Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004; 36(5):1011-9. DOI: 10.1097/00126334-200408150-00003. View

Sanne I, Piliero P, Squires K, Thiry A, Schnittman S . Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003; 32(1):18-29. DOI: 10.1097/00126334-200301010-00004. View

Levey A, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S . Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145(4):247-54. DOI: 10.7326/0003-4819-145-4-200608150-00004. View

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C . Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008; 197(1):102-8. DOI: 10.1086/524061. View

Hammer S, Saag M, Schechter M, Montaner J, Schooley R, Jacobsen D . Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006; 296(7):827-43. DOI: 10.1001/jama.296.7.827. View

10.

Kilby J, Hill A, Buss N . The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med. 2002; 3(2):97-104. DOI: 10.1046/j.1468-1293.2002.00090.x. View

11.

Wire M, Shelton M, Studenberg S . Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006; 45(2):137-68. DOI: 10.2165/00003088-200645020-00002. View

12.

Taburet A, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V . Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004; 48(6):2091-6. PMC: 415627. DOI: 10.1128/AAC.48.6.2091-2096.2004. View

13.

Power I, Cumming A, Pugh G . Effect of diclofenac on renal function and prostacyclin generation after surgery. Br J Anaesth. 1992; 69(5):451-6. DOI: 10.1093/bja/69.5.451. View

14.

Ruane P, Luber A, Wire M, Lou Y, Shelton M, Lancaster C . Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006; 51(2):560-5. PMC: 1797779. DOI: 10.1128/AAC.00560-06. View

15.

Cooper C, van Heeswijk R, Gallicano K, Cameron D . A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003; 36(12):1585-92. DOI: 10.1086/375233. View

16.

Gazzard B, Bernard A, Boffito M, Churchill D, Edwards S, Fisher N . British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006; 7(8):487-503. DOI: 10.1111/j.1468-1293.2006.00424.x. View

17.

Le Tiec C, Barrail A, Goujard C, Taburet A . Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005; 44(10):1035-50. DOI: 10.2165/00003088-200544100-00003. View

18.

Sale M, Sadler B, Stein D . Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002; 46(3):746-54. PMC: 127459. DOI: 10.1128/AAC.46.3.746-754.2002. View

19.

Orrick J, Steinhart C . Atazanavir. Ann Pharmacother. 2004; 38(10):1664-74. DOI: 10.1345/aph.1D394. View

20.

Chittick G, Zong J, Blum M, Sorbel J, Begley J, Adda N . Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother. 2006; 50(4):1304-10. PMC: 1426992. DOI: 10.1128/AAC.50.4.1304-1310.2006. View